Drottning Silvias barn- och ungdomssjukhus

BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. METHODS: We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis. RESULTS: In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS: Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug. (Funded by Biogen and Ionis Pharmaceuticals; ENDEAR ClinicalTrials.gov number, NCT02193074 .).

BACKGROUND: Nusinersen is an antisense oligonucleotide drug that modulates pre-messenger RNA splicing of the survival motor neuron 2 ( SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). METHODS: We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2:1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure (control group) on days 1, 29, 85, and 274. The primary end point was the least-squares mean change from baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 0 to 66, with higher scores indicating better motor function. Secondary end points included the percentage of children with a clinically meaningful increase from baseline in the HFMSE score (≥3 points), an outcome that indicates improvement in at least two motor skills. RESULTS: In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) and a least-squares mean decrease in the control group (by -1.9 points), with a significant between-group difference favoring nusinersen (least-squares mean difference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P<0.001). This result prompted early termination of the trial. Results of the final analysis were consistent with results of the interim analysis. In the final analysis, 57% of the children in the nusinersen group as compared with 26% in the control group had an increase from baseline to month 15 in the HFMSE score of at least 3 points (P<0.001), and the overall incidence of adverse events was similar in the nusinersen group and the control group (93% and 100%, respectively). CONCLUSIONS: Among children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals; CHERISH ClinicalTrials.gov number, NCT02292537 .).

BACKGROUND: An increased prevalence of asthma/recurrent wheeze (RW), clinical allergy and allergic sensitisation up to age 13&emsp14;years has previously been reported in subjects hospitalised with respiratory syncytial virus (RSV) bronchiolitis in their first year of life compared with matched controls. A study was undertaken to examine whether these features persist into early adulthood, to report longitudinal wheeze and allergy patterns, and to see how large and small airway function relates to RSV infection and asthma. METHODS: Follow-up at age 18 years was performed in 46 of 47 subjects with RSV and 92 of 93 controls. Assessments included questionnaire, clinical examination, skin prick tests, serum IgE antibodies to inhaled allergens, blood eosinophils, fraction of exhaled nitric oxide (FeNO), spirometry, multiple breath washout (lung clearance index, LCI) and dry air hyperventilation challenge. RESULTS: Increased prevalence of asthma/RW (39% vs 9%), clinical allergy (43% vs 17%) and sensitisation to perennial allergens (41% vs 14%) were present at age 18 in the RSV cohort compared with controls. Persistent/relapsing wheeze associated with early allergic sensitisation predominated in the RSV cohort compared with controls (30% vs 1%). Spirometric function was reduced in subjects with RSV with or without current asthma, but not in asthmatic controls. LCI was linked only to current asthma, airway hyperresponsiveness and FeNO. CONCLUSIONS: Severe early RSV bronchiolitis is associated with an increased prevalence of allergic asthma persisting into early adulthood. Small airway dysfunction (LCI) is related to current asthma and airway inflammation but not to RSV bronchiolitis. Reduced spirometry after RSV may reflect airway remodelling.

In 1995, a consensus statement was published for the purpose of summarizing the salient clinical features of Angelman syndrome (AS) to assist the clinician in making a timely and accurate diagnosis. Considering the scientific advances made in the last 10 years, it is necessary now to review the validity of the original consensus criteria. As in the original consensus project, the methodology used for this review was to convene a group of scientists and clinicians, with experience in AS, to develop a concise consensus statement, supported by scientific publications where appropriate. It is hoped that this revised consensus document will facilitate further clinical study of individuals with proven AS, and assist in the evaluation of those who appear to have clinical features of AS but have normal laboratory diagnostic testing.

In a representative series of 176 children with cerebral palsy (CP), aged 5 to 8 years, associations were studied between additional neuroimpairments, activity limitations, and participation restrictions in the domains of mobility, education, and social relations as proposed in the International Classification of Functioning Disability and Health (ICF). Learning disability occurred in 40%, epilepsy in 35%, visual impairment in 20%, and infantile hydrocephalus in 9% of the children. Additional neuroimpairments were most frequently seen in children with tetraplegia and dystonic CP and in those with antecedents of brain malformations or severe perinatal compromise. Activity limitations were studied with the Gross Motor Function Classification System (GMFCS) and a system for grading bimanual fine motor function (BFMF) was developed. There was a strong correlation of 0.74 between the GMFCS and BFMF ( p &lt;0.001). Learning disability, activity limitations, and participation restrictions were all clinically strongly associated with each other ( p &lt;0.001). Restriction in mobility was best predicted by the GMFCS, learning disability, and the BFMF; in education by learning disability and the GFMCS; and in social relations by learning disability, the GMFCS, and BFMF. Motor function and learning disability were important predictors for participation restrictions in children with CP. The ICF has the capacity to be a model to help plan interventions for specific functional goals and to ascertain the child's participation in society.

In a representative series of 176 children with cerebral palsy (CP), aged 5 to 8 years, associations were studied between additional neuroimpairments, activity limitations, and participation restrictions in the domains of mobility, education, and social relations as proposed in the International Classification of Functioning Disability and Health (ICF). Learning disability occurred in 40%, epilepsy in 35%, visual impairment in 20%, and infantile hydrocephalus in 9% of the children. Additional neuroimpairments were most frequently seen in children with tetraplegia and dystonic CP and in those with antecedents of brain malformations or severe perinatal compromise. Activity limitations were studied with the Gross Motor Function Classification System (GMFCS) and a system for grading bimanual fine motor function (BFMF) was developed. There was a strong correlation of 0.74 between the GMFCS and BFMF (p<0.001). Learning disability, activity limitations, and participation restrictions were all clinically strongly associated with each other (p<0.001). Restriction in mobility was best predicted by the GMFCS, learning disability, and the BFMF; in education by learning disability and the GFMCS; and in social relations by learning disability, the GMFCS, and BFMF. Motor function and learning disability were important predictors for participation restrictions in children with CP. The ICF has the capacity to be a model to help plan interventions for specific functional goals and to ascertain the child's participation in society.

The Manual Ability Classification System (MACS) has been developed to classify how children with cerebral palsy (CP) use their hands when handling objects in daily activities. The classification is designed to reflect the child's typical manual performance, not the child's maximal capacity. It classifies the collaborative use of both hands together. Validation was based on the experience within an expert group, a review of the literature, and thorough analysis of children across a spectrum of function. Discussions continued until consensus was reached, first about the constructs, then about the content of the five levels. Parents and therapists were interviewed about the content and the description of levels. Reliability was tested between pairs of therapists for 168 children (70 females, 98 males; with hemiplegia [n= 52], diplegia [n= 70], tetraplegia [n= 19], ataxia [n= 6], dyskinesia [n= 19], and unspecified CP [n= 2]) between 4 and 18 years and between 25 parents and their children's therapists. The results demonstrated that MACS has good validity and reliability. The intraclass correlation coefficient between therapists was 0.97 (95% confidence interval 0.96–0.98), and between parents and therapist was 0.96 (0.89-0.98), indicating excellent agreement.

BACKGROUND: C-reactive protein (CRP) is a heritable marker of chronic inflammation that is strongly associated with cardiovascular disease. We sought to identify genetic variants that are associated with CRP levels. METHODS AND RESULTS: We performed a genome-wide association analysis of CRP in 66 185 participants from 15 population-based studies. We sought replication for the genome-wide significant and suggestive loci in a replication panel comprising 16 540 individuals from 10 independent studies. We found 18 genome-wide significant loci, and we provided evidence of replication for 8 of them. Our results confirm 7 previously known loci and introduce 11 novel loci that are implicated in pathways related to the metabolic syndrome (APOC1, HNF1A, LEPR, GCKR, HNF4A, and PTPN2) or the immune system (CRP, IL6R, NLRP3, IL1F10, and IRF1) or that reside in regions previously not known to play a role in chronic inflammation (PPP1R3B, SALL1, PABPC4, ASCL1, RORA, and BCL7B). We found a significant interaction of body mass index with LEPR (P<2.9×10(-6)). A weighted genetic risk score that was developed to summarize the effect of risk alleles was strongly associated with CRP levels and explained ≈5% of the trait variance; however, there was no evidence for these genetic variants explaining the association of CRP with coronary heart disease. CONCLUSIONS: We identified 18 loci that were associated with CRP levels. Our study highlights immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation.

ABSTRACT: Hagberg, B., Hagberg, G. and Olow, I. (Department of Paediatrics II, Children's Hospital and the Habilitation Unit of Bräcke‐Östergård, Gothenburg, Sweden). The changing panorama of cerebral palsy in Sweden 1954–1970. I. Analysis of the general changes. Acta Paediatr Scand 64:187, 1975 From an unselected series of 560 cases of cerebral palsy in Sweden, born 1954‐70, the changes in incidence through the four periods 1954‐58, 1959‐62, 1963‐66 and 1967‐70 were analysed. The total incidence successively and significantly decreased from 2·2 % 0 in the first period to 1·3 % 0 in the last. This decrease was mainly related to (1) the syndromes of spastic and ataxic diplegia, (2) the low birth weight babies, and (3) the group with perinatal causes. The decrease was not related to any special intelligence quotient or geographical region.

UNLABELLED: This 8th Swedish population-based cerebral palsy (CP) report comprises 241 children born 1991-94. The live birth prevalence was 2.12 per 1000. Excluding 7 postnatally-derived cases, the gestational age-specific prevalences were 86 for extremely preterm children, 60 for very preterm and 6 for moderately preterm, and 1.3 for term children per 1000. Spastic hemiplegic, diplegic and tetraplegic subtypes accounted for 33%, 44% and 6%, dyskinetic CP for 12% and simple ataxia for 4%. Neuroimaging had been performed in 90%. Probable aetiology was identified in 73% of preterm and 86% of term children. Among preterm children it was considered prenatal in 12%, peri/neonatal in 61% and unclassifiable in 27%, while it was 51%, 36% and 14% among term children. CONCLUSION: The live birth prevalence for CP in the birth year period 1991-94 continued to decrease slightly. Gestational age-specific prevalences increased marginally in extremely and very preterm births, continued to decrease in moderately preterm births and decreased slightly in term births. Probable aetiology and timing of the brain insult could be revealed in 81%, birth asphyxia being the likely cause in 28% of term children.

OBJECTIVE: To evaluate the use of pulse oximetry to screen for early detection of life threatening congenital heart disease. DESIGN: Prospective screening study with a new generation pulse oximeter before discharge from well baby nurseries in West Götaland. Cohort study comparing the detection rate of duct dependent circulation in West Götaland with that in other regions not using pulse oximetry screening. Deaths at home with undetected duct dependent circulation were included. SETTING: All 5 maternity units in West Götaland and the supraregional referral centre for neonatal cardiac surgery. PARTICIPANTS: 39,821 screened babies born between 1 July 2004 and 31 March 2007. Total duct dependent circulation cohorts: West Götaland n=60, other referring regions n=100. MAIN OUTCOME MEASURES: Sensitivity, specificity, positive and negative predictive values, and likelihood ratio for pulse oximetry screening and for neonatal physical examination alone. RESULTS: In West Götaland 29 babies in well baby nurseries had duct dependent circulation undetected before neonatal discharge examination. In 13 cases, pulse oximetry showed oxygen saturations <or=90%, and (in accordance with protocol) clinical staff were immediately told of the results. Of the remaining 16 cases, physical examination alone detected 10 (63%). Combining physical examination with pulse oximetry screening had a sensitivity of 24/29 (82.8% (95% CI 64.2% to 95.2%)) and detected 100% of the babies with duct dependent lung circulation. Five cases were missed (all with aortic arch obstruction). False positive rate with pulse oximetry was substantially lower than that with physical examination alone (69/39 821 (0.17%) v 729/38 413 (1.90%), P<0.0001), and 31/69 of the "false positive" cases with pulse oximetry had other pathology. Thus, referral of all cases with positive oximetry results for echocardiography resulted in only 2.3 echocardiograms with normal cardiac findings for every true positive case of duct dependent circulation. In the cohort study, the risk of leaving hospital with undiagnosed duct dependent circulation was 28/100 (28%) in other referring regions versus 5/60 (8%) in West Götaland (P=0.0025, relative risk 3.36 (95% CI 1.37 to 8.24)). In the other referring regions 11/25 (44%) of babies with transposition of the great arteries left hospital undiagnosed versus 0/18 in West Götaland (P=0.0010), and severe acidosis at diagnosis was more common (33/100 (33%) v 7/60 (12%), P=0.0025, relative risk 2.8 (1.3 to 6.0)). Excluding premature babies and Norwood surgery, babies discharged without diagnosis had higher mortality than those diagnosed in hospital (4/27 (18%) v 1/110 (0.9%), P=0.0054). No baby died from undiagnosed duct dependent circulation in West Götaland versus five babies from the other referring regions. CONCLUSION: Introducing pulse oximetry screening before discharge improved total detection rate of duct dependent circulation to 92%. Such screening seems cost neutral in the short term, but the probable prevention of neurological morbidity and reduced need for preoperative neonatal intensive care suggest that such screening will be cost effective long term.

The relative contributions of apoptosis and necrosis in brain injury have been a matter of much debate. Caspase-3 has been identified as a key protease in the execution of apoptosis, whereas calpains have mainly been implicated in excitotoxic neuronal injury. In a model of unilateral hypoxia-ischemia in 7-day-old rats, caspase-3-like activity increased 16-fold 24 h postinsult, coinciding with cleavage of the caspase-3 proenzyme and endogenous caspase-3 substrates. This activation was significantly decreased by pharmacological calpain inhibition, using CX295, a calpain inhibitor that did not inhibit purified caspase-3 in vitro. Activation of caspase-3 by m-calpain, but not μ-calpain, was facilitated in a dose-dependent manner in vitroby incubating cytosolic fractions, containing caspase-3 proform, with calpains. This facilitation required the presence of some active caspase-3 and could be abolished by including the specific calpain inhibitor calpastatin. This indicates that initial cleavage of caspase-3 by m-calpain, producing a 29-kDa fragment, facilitates the subsequent cleavage into active forms. This is the first report to our knowledge suggesting a direct link between the early, excitotoxic, calcium-mediated activation of calpain after cerebral hypoxia-ischemia and the subsequent activation of caspase-3, thus representing a tentative pathway of “pathological apoptosis.” The relative contributions of apoptosis and necrosis in brain injury have been a matter of much debate. Caspase-3 has been identified as a key protease in the execution of apoptosis, whereas calpains have mainly been implicated in excitotoxic neuronal injury. In a model of unilateral hypoxia-ischemia in 7-day-old rats, caspase-3-like activity increased 16-fold 24 h postinsult, coinciding with cleavage of the caspase-3 proenzyme and endogenous caspase-3 substrates. This activation was significantly decreased by pharmacological calpain inhibition, using CX295, a calpain inhibitor that did not inhibit purified caspase-3 in vitro. Activation of caspase-3 by m-calpain, but not μ-calpain, was facilitated in a dose-dependent manner in vitroby incubating cytosolic fractions, containing caspase-3 proform, with calpains. This facilitation required the presence of some active caspase-3 and could be abolished by including the specific calpain inhibitor calpastatin. This indicates that initial cleavage of caspase-3 by m-calpain, producing a 29-kDa fragment, facilitates the subsequent cleavage into active forms. This is the first report to our knowledge suggesting a direct link between the early, excitotoxic, calcium-mediated activation of calpain after cerebral hypoxia-ischemia and the subsequent activation of caspase-3, thus representing a tentative pathway of “pathological apoptosis.” hypoxia-ischemia aminomethylcoumarin DNA fragmentation factor 45 α-fodrin breakdown product inhibitor of caspase-activated DNase poly(ADP-ribose) polymerase dithiothreitol 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone t-butoxycarbonyl-Asp-(OMe)-fluoromethyl ketone phosphate-buffered saline polymerase chain reaction glyceraldehyde-3-phosphate dehydrogenase Leu-Tyr-AMC The relative contributions of necrosis and apoptosis to the injury that develops after cerebral hypoxia-ischemia (HI)1 has been a matter of much debate (1Lee J.M. Zipfel G.J. Choi D.W. Nature. 1999; 399: 7-14Crossref PubMed Scopus (1004) Google Scholar). Recent studies suggest that cell death after HI is different from developmentally regulated cell death in most cases and cannot appropriately be described as apoptotic (2MacManus J.P. Fliss H. Preston E. Rasquinha I. Tuor U. J. Cereb. Blood Flow Metab. 1999; 19: 502-510Crossref PubMed Scopus (38) Google Scholar, 3Jin K. Chen J. Nagayama T. Chen M. Sinclair J. Graham S.H. Simon R.P. J. Neurochem. 1999; 72: 1204-1214Crossref PubMed Scopus (69) Google Scholar, 4Ishimaru M.J. Ikonomidou C. Tenkova T.I. Der T.C. Dikranian K. Sesma M.A. Olney J.W. J. Comp. Neurol. 1999; 408: 461-476Crossref PubMed Scopus (188) Google Scholar, 5Portera-Cailliau C. Price D.L. Martin L.J. J. Comp. Neurol. 1997; 378: 70-87PubMed Google Scholar). Nevertheless, HI cell death shares important morphological and biochemical features with apoptotic cell death, such as activation of caspases and nucleosomal DNA fragmentation (6Zhu C. Wang X. Hagberg H. Blomgren K. J. Neurochem. 2000; 75: 819-829Crossref PubMed Scopus (111) Google Scholar, 7Linnik M.D. Zobrist R.H. Hatfield M.D. Stroke. 1993; 24: 2002-2008Crossref PubMed Scopus (675) Google Scholar, 8MacManus J.P. Buchan A.M. Hill I.E. Rasquinha I. Preston E. Neurosci. Lett. 1993; 164: 89-92Crossref PubMed Scopus (450) Google Scholar, 9Cheng Y. Deshmukh M. DaCosta A. Demaro J.A. Gidday J.M. Shah A. Sun Y. Jacquin M.F. Johnson E.M. Holtzman D.M. J. Clin. Invest. 1998; 101: 1992-1999Crossref PubMed Scopus (481) Google Scholar, 10Namura S. Zhu J. Fink K. Endres M. Srinivasan A. Tomaselli K.J. Yuan J. Moskowitz M.A. J. Neurosci. 1998; 18: 3659-3668Crossref PubMed Google Scholar, 11Chen J. Nagayama T. Jin K. Stetler R.A. Zhu R.L. Graham S.H. Simon R.P. J. Neurosci. 1998; 18: 4914-4928Crossref PubMed Google Scholar, 12Pulera M.R. Adams L.M. Liu H. Santos D.G. Nishimura R.N. Yang F. Cole G.M. Wasterlain C.G. Stroke. 1998; 29: 2622-2630Crossref PubMed Scopus (180) Google Scholar, 13Ni B. Wu X. Su Y. Stephenson D. Smalstig E.B. Clemens J. Paul S.M. J. Cereb. Blood Flow Metab. 1998; 18: 248-256Crossref PubMed Scopus (147) Google Scholar, 14Ma J. Endres M. Moskowitz M.A. Br. J. Pharmacol. 1998; 124: 756-762Crossref PubMed Scopus (156) Google Scholar, 15Endres M. Namura S. Shimizu-Sasamata M. Waeber C. Zhang L. Gomez-Isla T. Hyman B.T. Moskowitz M.A. J. Cereb. Blood Flow Metab. 1998; 18: 238-247Crossref PubMed Scopus (509) Google Scholar, 16Hara H. Friedlander R.M. Gagliardini V. Ayata C. Fink K. Huang Z. Shimizu-Sasamata M. Yuan J. Moskowitz M.A. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2007-2012Crossref PubMed Scopus (798) Google Scholar, 17Yue X. Mehmet H. Penrice J. Cooper C. Cady E. Wyatt J.S. Reynolds E.O. Edwards A.D. Squier M.V. Neuropathol. Appl. Neurobiol. 1997; 23: 16-25Crossref PubMed Scopus (177) Google Scholar). Caspases, a family of cysteine proteases with an unusual substrate specificity, requiring an aspartate residue in the P1 position, have been identified as key executors of apoptosis (18Stennicke H.R. Salvesen G.S. Biochim. Biophys. Acta. 2000; 1477: 299-306Crossref PubMed Scopus (295) Google Scholar). Calpains, another family of cysteine proteases, are calcium-activated and are proposed to participate in the turnover of cytoskeletal proteins and regulation of kinases, transcription factors, and receptors (19Chan S.L. Mattson M.P. J. Neurosci. Res. 1999; 58: 167-190Crossref PubMed Scopus (372) Google Scholar, 20Sorimachi H. Ishiura S. Suzuki K. Biochem. J. 1997; 328: 721-732Crossref PubMed Scopus (620) Google Scholar). Calpains have mainly been implicated in excitotoxic neuronal injury and necrosis (21Seubert P. Lee K. Lynch G. Brain Res. 1989; 492: 366-370Crossref PubMed Scopus (189) Google Scholar, 22Siman R. Noszek J. Neuron. 1988; 1: 279-287Abstract Full Text PDF PubMed Scopus (381) Google Scholar, 23Bednarski E. Vanderklish P. Gall C. Saido T. Bahr B. Lynch G. Brain Res. 1995; 694: 147-157Crossref PubMed Scopus (61) Google Scholar). Pharmacological inhibitors of calpains and caspases exert cerebroprotective effects (9Cheng Y. Deshmukh M. DaCosta A. Demaro J.A. Gidday J.M. Shah A. Sun Y. Jacquin M.F. Johnson E.M. Holtzman D.M. J. Clin. Invest. 1998; 101: 1992-1999Crossref PubMed Scopus (481) Google Scholar, 14Ma J. Endres M. Moskowitz M.A. Br. J. Pharmacol. 1998; 124: 756-762Crossref PubMed Scopus (156) Google Scholar, 15Endres M. Namura S. Shimizu-Sasamata M. Waeber C. Zhang L. Gomez-Isla T. Hyman B.T. Moskowitz M.A. J. Cereb. Blood Flow Metab. 1998; 18: 238-247Crossref PubMed Scopus (509) Google Scholar, 16Hara H. Friedlander R.M. Gagliardini V. Ayata C. Fink K. Huang Z. Shimizu-Sasamata M. Yuan J. Moskowitz M.A. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2007-2012Crossref PubMed Scopus (798) Google Scholar, 24Lee K. Frank S. Vanderklish P. Arai A. Lynch G. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 7233-7237Crossref PubMed Scopus (333) Google Scholar, 25Rami A. Krieglstein J. Brain Res. 1993; 609: 67-70Crossref PubMed Scopus (164) Google Scholar, 26Bartus R. Hayward N. Elliott P. Sawyer S. Baker K. Dean R. Akiyama A. Straub J. Harbeson S. Li Z. Powers J. Stroke. 1994; 25: 2265-2270Crossref PubMed Scopus (198) Google Scholar). A growing body of literature has emerged, demonstrating functional connections between calpains and caspases (27Wang K.K. Trends Neurosci. 2000; 23: 20-26Abstract Full Text Full Text PDF PubMed Scopus (811) Google Scholar). Common substrate proteins have been identified, such as fodrin (28Nath R. Raser K. Stafford D. Hajimohammadreza I. Posner A. Allen H. Talanian R. Yuen P. Gilbertsen R. Wang K. Biochem. J. 1996; 319: 683-690Crossref PubMed Scopus (398) Google Scholar, 29Jänicke R. Ng P. Sprengart M. Porter A. J. Biol. Chem. 1998; 273: 15540-15545Abstract Full Text Full Text PDF PubMed Scopus (444) Google Scholar, 30Vanags D. Pörn-Ares M. Coppola S. Burgess D. Orrenius S. J. Biol. Chem. 1996; 271: 31075-31085Abstract Full Text Full Text PDF PubMed Scopus (356) Google Scholar, 31Wang K. Posmantur R. Nath R. McGinnis K. Whitton M. Talanian R. Galntz S. Morrow J. J. Biol. Chem. 1998; 273: 22490-22497Abstract Full Text Full Text PDF PubMed Scopus (283) Google Scholar), calpastatin (32Pörn-Ares M.I. Samali A. Orrenius S. Cell Death Differ. 1998; 5: 1028-1033Crossref PubMed Scopus (184) Google Scholar, 33Wang K.K. Posmantur R. Nadimpalli R. Nath R. Mohan P. Nixon R.A. Talanian R.V. Keegan M. Herzog L. Allen H. Arch. Biochem. Biophys. 1998; 356: 187-196Crossref PubMed Scopus (231) Google Scholar), actin (34Villa P.G. Henzel W.J. Sensenbrenner M. Henderson C.E. Pettmann B. J. Cell Sci. 1998; 111: 713-722PubMed Google Scholar), PARP (35McGinnis N. Wang K.K. Biochem. Biophys. Res. 1999; PubMed Scopus Google Scholar), and N. L. C. C. A.M. M. A. A. P. J. Neurosci. 1998; 18: PubMed Google Scholar). are demonstrating cleavage of caspase-3 (35McGinnis N. Wang K.K. Biochem. Biophys. Res. 1999; PubMed Scopus Google Scholar, H.R. H. Salvesen G.S. 1999; 94: PubMed Google and A. G. J. 1999; 18: PubMed Scopus Google Scholar, B.T. K. Li P. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google as as and B.T. K. Li P. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). the was by calpain apoptosis of A. Y. 1998; PubMed Scopus Google Scholar), and calpain be the in an into a T. Yuan J. J. Cell Biol. 2000; PubMed Scopus Google Scholar). between calpains and the of caspases in apoptosis of B. J. J. Biol. Chem. 1998; 273: Full Text Full Text PDF PubMed Scopus Google Scholar), whereas studies an calpains in the apoptosis of A.M. E. J. 1999; PubMed Scopus Google and M. J. J. 1997; Google Scholar). and Yuan that be the activation of by the a link between and apoptosis T. Yuan J. J. Cell Biol. 2000; PubMed Scopus Google Scholar). that the of calpastatin in a model of cerebral HI a K. U. M. Bahr A. Saido T.C. S. Hagberg H. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar), the the activation of demonstrating of calpastatin by caspase-3 (32Pörn-Ares M.I. Samali A. Orrenius S. Cell Death Differ. 1998; 5: 1028-1033Crossref PubMed Scopus (184) Google Scholar, 33Wang K.K. Posmantur R. Nadimpalli R. Nath R. Mohan P. Nixon R.A. Talanian R.V. Keegan M. Herzog L. Allen H. Arch. Biochem. Biophys. 1998; 356: 187-196Crossref PubMed Scopus (231) Google to the and activation of proteases and in HI was in 7-day-old of J. R. J. Neurol. PubMed Scopus Google Scholar, H. E. N. P. Biol. 1994; PubMed Scopus Google Scholar). The with and in a of and and the of was The was between of the the with a and the to The in a with a in The in the was the to and but not to was by the of with the calpain inhibitor The first of in to body was after with of the to body h 24 with The by and the a of in and and to the was from The was by in of containing and with an of and active caspase-3 of of caspase-3 is not was with of protease inhibitor and with of substrate in containing and of was using a with an of and an of cleavage was from and as relative S. C. E. Biochem. J. PubMed Scopus Google of from the in of was with of inhibitor and with of in containing and cleavage was as described the caspase-3 as from and benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone ketone from of with of containing and a of in inhibitors but with was of was as described and as of of and The caspase-3 and the of caspase-3 the a from The the active of caspase-3 in (6Zhu C. Wang X. Hagberg H. Blomgren K. J. Neurochem. 2000; 75: 819-829Crossref PubMed Scopus (111) Google Scholar). A that the breakdown product of α-fodrin was to fodrin cleavage B. S. G. Lynch G. J. Pharmacol. 1995; 273: Google Scholar). The was and was by with a X. H. C. Wang X. 1997; Full Text Full Text PDF PubMed Scopus Google from of The The PARP fodrin and and from The of the fodrin was by incubating a with caspase-3 The and the to and In the with m-calpain, a with In the with caspase-3, could be using the of fodrin was as using the that the fodrin as as cleavage The of in was to J. K. C. M. Biochem. 1994; PubMed Scopus Google Scholar). to of and to using and and using the in a and using the was and the was as of was by in with the was to between S. Zhu J. Fink K. Endres M. Srinivasan A. Tomaselli K.J. Yuan J. Moskowitz M.A. J. Neurosci. 1998; 18: 3659-3668Crossref PubMed Google Scholar). and with in The and 24 with and the and into in and in in a of in and as with in was by the in was with in was in and by in was using and as The was in containing and by in was using 24 and of after and The and in was from P. N. Biochem. PubMed Scopus Google Scholar), and was with the and and to 24 The was and of first of and of of and and by was and the reaction was to by of The thus was to with and subsequent of a of and a of of DNA polymerase and of as caspase-3 and and from caspase-3 was as 24 of was as of The and such that the caspase-3 and the be in the of and of not The caspase-3 and with and The and the using the The relative of caspase-3 was after to to the of the of the of in of and 45 to cytosolic of of of of of the in in the and of m-calpain, caspase-3, purified calpastatin calpastatin was in some the inhibitors with the to the The by of of and to of to and The to and Biochem. PubMed Scopus Google Scholar), using a calpastatin was purified from as described S. C. E. Biochem. J. PubMed Scopus Google and purified acid and B. J. Blomgren K. J. Arch. 1988; PubMed Scopus Google Scholar). of the was of active caspase-3 is as the of caspase-3 that of in the described to caspase-3 could the activity activity was as described of with activity was in brain and increased in the with the in with (9Cheng Y. Deshmukh M. DaCosta A. Demaro J.A. Gidday J.M. Shah A. Sun Y. Jacquin M.F. Johnson E.M. Holtzman D.M. J. Clin. Invest. 1998; 101: 1992-1999Crossref PubMed Scopus (481) Google Scholar), and a 24 h The between the and was significantly decreased after calpain inhibition, from in the to in the of in calpain the activation of caspase-3-like activity cleavage of the caspase-3 and of endogenous caspase-3 substrate after with the calpain inhibitor h 24 h The between the and the is and the cleavage product of caspase-3 the is that between the and the in the could not be in the in a The caspase-3-like activity cleavage of the caspase-3 and of endogenous caspase-3 substrate after with the calpain inhibitor h 24 h The between the and the is and the cleavage product of caspase-3 the is that between the and the in the could not be in the The caspase-3 a with of and The of caspase-3 as the brain the the The was after HI h to h after the with of and in the The of the and to a of the as by a decreased This of the to a 24 h a the activity The 29-kDa was in from to h whereas the was in mainly 24 h was with some the and a The activation of caspase-3, as by the and of the proform, was in by the of the and the by the of the and in the The of the between the and the was significantly increased after calpain inhibition, from in the to in the The between the and in the a from in the to in the The of the active cleavage of the the caspase-3-like activity was with the and the 29-kDa from the 24 h The between the and the a with the activity and did the 29-kDa The a caspase-3 and a fragment, as The most after to was that the of caspase-3 an from to to the The by The of was to and m-calpain, but did not inhibit caspase-3 The of a inhibitor of was calpains caspase-3 another caspase-3 much calpains the protease inhibitors inhibitor the proteases activity in are of the inhibitors the active cysteine but with different was to caspase-3, and was to and in a The inhibitor the proteases activity in are of the inhibitors the active cysteine but with different was to caspase-3, and was to and The of and PARP a 24 h with the activity the and of but specific could be using The of in the to a decreased and between the and the This was significantly increased after calpain inhibition, from in the to in the of the PARP was by an increased of fodrin the and as as the cleavage The caspase-3 was to be specific caspase-3 in and was in with as by the of and with DNA (6Zhu C. Wang X. Hagberg H. Blomgren K. J. Neurochem. 2000; 75: 819-829Crossref PubMed Scopus (111) Google Scholar). The of by the increased and was 24 h h A and The in of but a of after HI A and of caspase-3 and of and active is of using the active caspase-3 and and 24 h of demonstrating the of caspase-3 and calpain activity 24 h of the calpain activity has but the of active caspase-3 has of did not the cleavage the caspase-3 A and was a 29-kDa to the after HI in This did not an of was was with calpastatin purified CX295, HI in was the the of the that was and This was not by calpain purified by but could be by and calpain The caspase-3-like activity increased after of from different with and could be abolished calpastatin was in the was in the the activity was not significantly increased of active caspase-3 to cytosolic fractions, the active caspase-3 could be as a as an of active caspase-3 the of the 29-kDa from the The of the 29-kDa was by including of active caspase-3 to the the activity increased caspase-3 was in the of This could be abolished by including in the Caspase-3 could not m-calpain, incubating with of caspase-3 did not the calpain activity between and A cytosolic containing caspase-3 proform, was with and different of caspase-3 and as active caspase-3 was the of a in the demonstrating the the relative in caspase-3-like activity in the is in the a caspase-3 that the active caspase-3 be as a as the of active caspase-3 an increased of the 29-kDa but was active as that the some endogenous m-calpain, in to caspase-3 a demonstrating that the of caspase-3 cleavage in the was not to is that in a producing an the The cleavage of the from to was could be by and calpastatin not inhibit m-calpain, but not μ-calpain, could cleavage of the of producing a 29-kDa could be This is the report to our knowledge demonstrating a functional in substrate between the calpains. Recent studies have cleavage of caspase-3 by producing an cleavage product (35McGinnis N. Wang K.K. Biochem. Biophys. Res. 1999; PubMed Scopus Google Scholar, H.R. H. Salvesen G.S. 1999; 94: PubMed Google Scholar), but another report to such cleavage A. G. J. 1999; 18: PubMed Scopus Google Scholar). H.R. H. Salvesen G.S. 1999; 94: PubMed Google identified the cleavage in the of In was not m-calpain, of could functional that calpains are to and that calpains as of B.T. K. Li P. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). of studies calpastatin to the the first to that calpains H.R. H. Salvesen G.S. 1999; 94: PubMed Google Scholar), is important to in using as a that was calpains and that was with to between calpain and the effects cysteine proteases have not been purified caspase-3 was not to caspase-3 is the cytosolic from containing of This that and but the cannot be that have been the The of a and and is that was the that was HI in This indicates that are of the caspase-3 and that the of to active is different in is not the are the of The caspase-3-like activity was with the of the and the that the 29-kDa be an in the of the active The that of 29-kDa caspase-3 activity indicates that the to the active be facilitated by initial cleavage in the This was by the that and caspase-3 to be active to that the initial of the 29-kDa was by cleavage into the active was that the was to activation of m-calpain, the activity of the activity was could not be by the of active caspase-3 The was by that a of caspase-3, with a of m-calpain, the of the 29-kDa as as the caspase-3 was The activation of first calpain and caspase-3 after HI was to in the and in of of This with an model of of caspase-3 activation the of neuronal has been that calpain activation after in an the and a coinciding with (21Seubert P. Lee K. Lynch G. Brain Res. 1989; 492: 366-370Crossref PubMed Scopus (189) Google Scholar, T. M. K. E. Y. S. J. Biol. Chem. 1994; Full Text PDF PubMed Google Scholar). This of fodrin was in our model K. S. Saido T. J. A. Hagberg H. Brain Res. 1995; PubMed Scopus Google Scholar), but the of calpastatin was K. U. M. Bahr A. Saido T.C. S. Hagberg H. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). is not calpains caspase-3, the calpastatin have been to (32Pörn-Ares M.I. Samali A. Orrenius S. Cell Death Differ. 1998; 5: 1028-1033Crossref PubMed Scopus (184) Google Scholar, 33Wang K.K. Posmantur R. Nadimpalli R. Nath R. Mohan P. Nixon R.A. Talanian R.V. Keegan M. Herzog L. Allen H. Arch. Biochem. Biophys. 1998; 356: 187-196Crossref PubMed Scopus (231) Google Scholar). The caspase-3 activity in was and is that activation of caspase-3 after HI is different from that developmentally regulated are of increased caspase-3 a after cerebral 7Linnik M.D. Zobrist R.H. Hatfield M.D. Stroke. 1993; 24: 2002-2008Crossref PubMed Scopus (675) Google Scholar, 8MacManus J.P. Buchan A.M. Hill I.E. Rasquinha I. Preston E. Neurosci. Lett. 1993; 164: 89-92Crossref PubMed Scopus (450) Google Scholar, and 10Namura S. Zhu J. Fink K. Endres M. Srinivasan A. Tomaselli K.J. Yuan J. Moskowitz M.A. J. Neurosci. 1998; 18: 3659-3668Crossref PubMed Google Scholar, 11Chen J. Nagayama T. Jin K. Stetler R.A. Zhu R.L. Graham S.H. Simon R.P. J. Neurosci. 1998; 18: 4914-4928Crossref PubMed Google Scholar, 12Pulera M.R. Adams L.M. Liu H. Santos D.G. Nishimura R.N. Yang F. Cole G.M. Wasterlain C.G. Stroke. 1998; 29: 2622-2630Crossref PubMed Scopus (180) Google as as of after of inhibitors 9Cheng Y. Deshmukh M. DaCosta A. Demaro J.A. Gidday J.M. Shah A. Sun Y. Jacquin M.F. Johnson E.M. Holtzman D.M. J. Clin. Invest. 1998; 101: 1992-1999Crossref PubMed Scopus (481) Google and 14Ma J. Endres M. Moskowitz M.A. Br. J. Pharmacol. 1998; 124: 756-762Crossref PubMed Scopus (156) Google Scholar, 15Endres M. Namura S. Shimizu-Sasamata M. Waeber C. Zhang L. Gomez-Isla T. Hyman B.T. Moskowitz M.A. J. Cereb. Blood Flow Metab. 1998; 18: 238-247Crossref PubMed Scopus (509) Google Scholar, 16Hara H. Friedlander R.M. Gagliardini V. Ayata C. Fink K. Huang Z. Shimizu-Sasamata M. Yuan J. Moskowitz M.A. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2007-2012Crossref PubMed Scopus (798) Google Scholar), but the that to after the a link between and “pathological apoptosis.” This is by our that the caspase-3 activation after HI M. U. Zhu C. Wang X. Blomgren K. Hagberg H. 2000; PubMed Scopus Google Scholar). studies have that to the activation of T. Zhu H. N. Li E. J. Yuan J. Nature. 2000; PubMed Scopus Google Scholar), by T. Yuan J. J. Cell Biol. 2000; PubMed Scopus Google Scholar). Liu Y. Blomgren K. J. Cereb. Blood Flow Metab. 2000; PubMed Scopus Google that of active caspase-3 in after but in B. Wu X. Su Y. Stephenson D. Smalstig E.B. Clemens J. Paul S.M. J. Cereb. Blood Flow Metab. 1998; 18: 248-256Crossref PubMed Scopus (147) Google of caspase-3 in the and brain but in the Chen J. Nagayama T. Jin K. Stetler R.A. Zhu R.L. Graham S.H. Simon R.P. J. Neurosci. 1998; 18: 4914-4928Crossref PubMed Google of caspase-3 and in the of an in the after h of after in the with of caspase-3 and but the the to be after HI in the The of calpains K. J. Neurochem. Res. 1989; PubMed Scopus Google and caspase-3 is in the that proteases be important in the In is the first report to our knowledge demonstrating a functional in the substrate of the calpains and as as facilitated activation of caspase-3 by Caspase-3 has been identified as a key protease in the execution of apoptosis, whereas calpains have mainly been implicated in excitotoxic neuronal injury. suggest a direct link between the early, excitotoxic, calcium-mediated activation of calpains after cerebral HI and the subsequent activation of caspase-3, thus representing a tentative pathway of “pathological apoptosis.” This be important in the brain of the of calpains and caspase-3 are to the active caspase-3 and to Wang of the

The presentation and clinical diagnosis of Rett syndrome at various ages and stages are reviewed. In addition to the classical form, variability in phenotype between different atypical Rett forms is given. Obligatory, supportive, and differential diagnostic criteria are summarized. Long-term follow-up findings in ageing Rett women are addressed.

OBJECTIVE: To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA). METHODS: This was an international, multicenter, randomized, placebo-controlled, double-blind study. One hundred twenty-two children with persistent polyarticular JRA despite prior methotrexate (MTX) therapy were randomized to receive infliximab or placebo for 14 weeks, after which all children received infliximab through week 44. Patients received MTX plus infliximab 3 mg/kg through week 44, or MTX plus placebo for 14 weeks followed by MTX plus infliximab 6 mg/kg through week 44. RESULTS: Although a higher proportion of patients in the 3 mg/kg infliximab group than in the placebo group had achieved responses according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) criteria for improvement at week 14 (63.8% and 49.2%, respectively), the between-group difference in this primary efficacy end point was not statistically significant (P = 0.12). By week 16, after the crossover from placebo to infliximab 6 mg/kg when all patients were receiving infliximab, an ACR Pedi 30 response was achieved in 73.2% of all patients. By week 52, ACR Pedi 50 and ACR Pedi 70 responses had been reached in 69.6% and 51.8%, respectively, of patients. Infliximab was generally well tolerated, but the safety profile of infliximab 3 mg/kg appeared less favorable than that of infliximab 6 mg/kg, with more frequent occurrences of serious adverse events, infusion reactions, antibodies to infliximab, and newly induced antinuclear antibodies and antibodies to double-stranded DNA observed with the 3 mg/kg dose. CONCLUSION: While infliximab at 3 mg/kg and 6 mg/kg showed durable efficacy at 1 year, achievement of the primary efficacy end point at 3 months did not differ significantly between infliximab-treated and placebo-treated patients. Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile. These results warrant further investigation in children with JRA.

Germline GATA2 mutations cause cellular deficiencies with high propensity for myeloid disease. We investigated 426 children and adolescents with primary myelodysplastic syndrome (MDS) and 82 cases with secondary MDS enrolled in 2 consecutive prospective studies of the European Working Group of MDS in Childhood (EWOG-MDS) conducted in Germany over a period of 15 years. Germline GATA2 mutations accounted for 15% of advanced and 7% of all primary MDS cases, but were absent in children with MDS secondary to therapy or acquired aplastic anemia. Mutation carriers were older at diagnosis and more likely to present with monosomy 7 and advanced disease compared with wild-type cases. For stratified analysis according to karyotype, 108 additional primary MDS patients registered with EWOG-MDS were studied. Overall, we identified 57 MDS patients with germline GATA2 mutations. GATA2 mutations were highly prevalent among patients with monosomy 7 (37%, all ages) reaching its peak in adolescence (72% of adolescents with monosomy 7). Unexpectedly, monocytosis was more frequent in GATA2-mutated patients. However, when adjusted for the selection bias from monosomy 7, mutational status had no effect on the hematologic phenotype. Finally, overall survival and outcome of hematopoietic stem cell transplantation (HSCT) were not influenced by mutational status. This study identifies GATA2 mutations as the most common germline defect predisposing to pediatric MDS with a very high prevalence in adolescents with monosomy 7. GATA2 mutations do not confer poor prognosis in childhood MDS. However, the high risk for progression to advanced disease must guide decision-making toward timely HSCT.

UNLABELLED: This study aimed to update growth reference values for height, weight and head circumference in order to reflect the changes in body size in the Swedish population during the past two decades. The data came from a large longitudinal growth study on 3650 full-term healthy Swedish children who were born between 1973 and 1975. All of these 1801 girls and 1849 boys had longitudinal data for height and weight from birth to final height. Comparison with previous Swedish growth reference values based on children born between 1955 and 1958 revealed that there have been secular changes in body size. For instance, at 18 y of age, the updated height and weight reference values are 180.4 cm for males and 167.7 cm for females, i.e. 1.9 cm taller and 5.7 kg heavier for males and 2.3 cm taller and 3.4 kg heavier for females compared with the previous reference values. CONCLUSION: These new growth reference values provide current national standards for growth monitoring and evaluation since the year 2000.

AIM: This is the ninth report from the western-Swedish study of the prevalence and origin of cerebral palsy. METHODS: A population-based study covering the 88 371 live births in the area in 1995-1998. Birth characteristics, neuroimaging findings and risk factors in children with cerebral palsy were recorded, prevalence was calculated, and aetiology was analysed. RESULTS: The study comprised 170 children with cerebral palsy, i.e. a prevalence of 1.92 per 1000 live births. Excluding eight post-neonatally derived cases, the gestational age-specific prevalences were 77 per 1000 for children born before 28 wk of gestation, 40 for children born at 28-31 wk, 7 for children born at 32-36 wk and 1.1 for children born after 36 wk of gestation. Spastic hemiplegia, diplegia and tetraplegia accounted for 38%, 35% and 6%, respectively, dyskinetic cerebral palsy for 15%, and ataxia for 6%. For the first time, hemiplegia was now most common, due to the decline in preterm diplegia. There was a further increase in full-term dyskinetic cerebral palsy. The origin of cerebral palsy in children born at term was considered to be prenatal in 38%, peri/neonatal in 35% and unclassifiable in 27%, while in children born preterm it was 17%, 49% and 33%, respectively. CONCLUSION: The decreasing trend from the period 1991-1994 continued, both in children born at term and especially in those born preterm. However, the increase in dyskinetic cerebral palsy in children born at term was a matter of concern. In this group, a perinatal hypoxic ischaemic encephalopathy had been present in 71%.

BACKGROUND: A sensitive and valid non-invasive marker of early cystic fibrosis (CF) lung disease is sought. The lung clearance index (LCI) from multiple-breath washout (MBW) is known to detect abnormal lung function more readily than spirometry in children and teenagers with CF, but its relationship to structural lung abnormalities is unknown. A study was undertaken to determine the agreements between LCI and spirometry, respectively, with structural lung disease as measured by high-resolution computed tomography (HRCT) in children and teenagers with CF. METHODS: A retrospective study was performed in 44 consecutive patients with CF aged 5-19 years (mean 12 years). At an annual check-up inspiratory and expiratory HRCT scans, LCI and spirometric parameters (forced expiratory volume in 1 s (FEV1) and maximal expiratory flow when 75% of forced vital capacity was expired (FEF75)) were recorded. Abnormal structure was defined as a composite HRCT score of >5%, the presence of bronchiectasis or air trapping >30%. Abnormal lung function was defined as LCI above the predicted mean +1.96 residual standard deviations (RSD), or FEV1 or FEF75 below the predicted mean -1.96 RSD. Sensitivity/specificity assessments and correlation analyses were done. RESULTS: The sensitivity to detect abnormal lung structure was 85-94% for LCI, 19-26% for FEV1 and 62-75% for FEF75. Specificity was 43-65% for LCI, 89-100% for FEV1 and 75-88% for FEF75. LCI correlated better with HRCT scores (Rs +0.85) than FEV1 (-0.62) or FEF75 (-0.66). CONCLUSIONS: LCI is a more sensitive indicator than FEV1 or FEF75 for detecting structural lung disease in CF, and a normal LCI almost excludes HRCT abnormalities. The finding of an abnormal LCI in some patients with normal HRCT scans suggests that LCI may be even more sensitive than HRCT scanning for detecting lung involvement in CF.

In this study we present incidence, point prevalence, and mortality figures of mitochondrial encephalomyopathies in a population-based study of children from western Sweden. Through the screening of registers and review of medical records, we identified 32 patients under 16 years of age from the study population who were diagnosed between January 1, 1984, and December 31, 1998. The incidence of mitochondrial encephalomyopathies in preschool children (<6 years of age) was 1 out of 11,000. The preschool incidence of Leigh's syndrome was 1 out of 32,000, and the preschool incidences of both Alper's syndrome and infantile mitochondrial myopathy with cytochrome C oxidase deficiency were 1 out of 51,000. The point prevalence January 1, 1999) of mitochondrial encephalomyopathies in children under 16 years of age was 1 out of 21,000. The median survival for patients with infantile onset was until 12 years of age. We identified 4 cases with mitochondrial DNA point mutations, 2 cases with mitochondrial DNA deletions, and 2 cases with nuclear mutations in the SURF1 gene. We conclude that mitochondrial encephalomyopathies are relatively common neurometabolic disorders in childhood.

OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of erythropoietin in neonatal hypoxic-ischemic encephalopathy (HIE), by using a randomized, prospective study design. METHODS: A total of 167 term infants with moderate/severe HIE were assigned randomly to receive either erythropoietin (N = 83) or conventional treatment (N = 84). Recombinant human erythropoietin, at either 300 U/kg (N = 52) or 500 U/kg (N = 31), was administered every other day for 2 weeks, starting <48 hours after birth. The primary outcome was death or disability. Neurodevelopmental outcomes were assessed at 18 months of age. RESULTS: Complete outcome data were available for 153 infants. Nine patients dropped out during treatment, and 5 patients were lost to follow-up monitoring. Death or moderate/severe disability occurred for 35 (43.8%) of 80 infants in the control group and 18 (24.6%) of 73 infants in the erythropoietin group (P = .017) at 18 months. The primary outcomes were not different between the 2 erythropoietin doses. Subgroup analyses indicated that erythropoietin improved long-term outcomes only for infants with moderate HIE (P = .001) and not those with severe HIE (P = .227). No negative hematopoietic side effects were observed. CONCLUSION: Repeated, low-dose, recombinant human erythropoietin treatment reduced the risk of disability for infants with moderate HIE, without apparent side effects.